133 related articles for article (PubMed ID: 38410594)
1. CtDNA based molecular residual disease outcompetes carcinoembryonic antigen in predicting postoperative recurrence of non-small cell lung cancer.
Li HJ; Zhang JT; Dong S; Yang XN; Cui SR; Wu YL; Zhong WZ
J Thorac Dis; 2024 Jan; 16(1):423-429. PubMed ID: 38410594
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA analysis predicts recurrence and avoids unnecessary adjuvant chemotherapy in I-IV colorectal cancer.
Fan W; Xia Z; Chen R; Lin D; Li F; Zheng Y; Luo J; Xiong Y; Yu P; Gao W; Gong Y; Zhang F; Zhang S; Li L
Ther Adv Med Oncol; 2024; 16():17588359231220607. PubMed ID: 38282662
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of postoperative longitudinal change of serum carcinoembryonic antigen level in patients with stage I lung adenocarcinoma completely resected by single-port video-assisted thoracic surgery: a retrospective study.
Chen H; Jiang Y; Jia K; Zhang K; Matsuura N; Jeong JY; Su B; Zhou X
Transl Lung Cancer Res; 2021 Oct; 10(10):3983-3994. PubMed ID: 34858786
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.
Jung HA; Ku BM; Kim YJ; Park S; Sun JM; Lee SH; Ahn JS; Cho JH; Kim HK; Choi YS; Choi YL; Shin SH; Jeong BH; Um SW; Kim H; Kim K; Ahn MJ; Kim J
J Thorac Oncol; 2023 Sep; 18(9):1199-1208. PubMed ID: 37308037
[TBL] [Abstract][Full Text] [Related]
5. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
[TBL] [Abstract][Full Text] [Related]
6. Investigate the application of postoperative ctDNA-based molecular residual disease detection in monitoring tumor recurrence in patients with non-small cell lung cancer--A retrospective study of ctDNA.
Zhang X; Zhang Y; Zhang S; Wang S; Yang P; Liu C
Front Oncol; 2023; 13():1098128. PubMed ID: 37091156
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR-TKI treatment in advanced non-small cell lung cancer.
Zheng J; Wang Y; Hu C; Zhu M; Ii J; Lin C; Lu C; Dou Y; Zhao C; Zhang Y; Wu D; Li L; Tang H; He T; Pan C; Han R; He Y
Thorac Cancer; 2022 Nov; 13(22):3162-3173. PubMed ID: 36193794
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients.
Yue D; Liu W; Chen C; Zhang T; Ma Y; Cui L; Gu Y; Bei T; Zhao X; Zhang B; Bai Y; Romero A; Xu-Welliver M; Wang C; Zhang Z; Zhang B
Transl Lung Cancer Res; 2022 Feb; 11(2):263-276. PubMed ID: 35280315
[TBL] [Abstract][Full Text] [Related]
9. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer.
Xia J; Zhang J; Xiong Y; Zhao J; Zhou Y; Jiang T; Zhu J
Expert Rev Mol Diagn; 2023; 23(10):913-924. PubMed ID: 37702546
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827
[TBL] [Abstract][Full Text] [Related]
12. Postoperative serum carcinoembryonic antigen levels in patients with pathologic stage IA nonsmall cell lung carcinoma: subnormal levels as an indicator of favorable prognosis.
Sawabata N; Maeda H; Yokota S; Takeda S; Koma M; Tokunaga T; Ito M
Cancer; 2004 Aug; 101(4):803-9. PubMed ID: 15305413
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of preoperative carcinoembryonic antigen/tumor size in rectal cancer.
Cai D; Huang ZH; Yu HC; Wang XL; Bai LL; Tang GN; Peng SY; Li YJ; Huang MJ; Cao GW; Wang JP; Luo YX
World J Gastroenterol; 2019 Sep; 25(33):4945-4958. PubMed ID: 31543685
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer.
Gaspar MJ; Diez M; Rodriguez A; Ratia T; Martin Duce A; Galvan M; Granell J; Coca C
Anticancer Res; 2003; 23(4):3427-32. PubMed ID: 12926084
[TBL] [Abstract][Full Text] [Related]
15. Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study.
Dong D; Zhang S; Jiang B; Wei W; Wang C; Yang Q; Yan T; Chen M; Zheng L; Shao W; Xiong G
Front Oncol; 2023; 13():1222716. PubMed ID: 37546402
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
[TBL] [Abstract][Full Text] [Related]
17. [Application Value of ctDNA-based MRD Dedection
in Early Stage Non-small Cell Lung Cancer after Radical Surgery].
Dou S; Xie H; Yang L
Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):862-866. PubMed ID: 34743498
[TBL] [Abstract][Full Text] [Related]
18. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
Parikh AR; Van Seventer EE; Siravegna G; Hartwig AV; Jaimovich A; He Y; Kanter K; Fish MG; Fosbenner KD; Miao B; Phillips S; Carmichael JH; Sharma N; Jarnagin J; Baiev I; Shah YS; Fetter IJ; Shahzade HA; Allen JN; Blaszkowsky LS; Clark JW; Dubois JS; Franses JW; Giantonio BJ; Goyal L; Klempner SJ; Nipp RD; Roeland EJ; Ryan DP; Weekes CD; Wo JY; Hong TS; Bordeianou L; Ferrone CR; Qadan M; Kunitake H; Berger D; Ricciardi R; Cusack JC; Raymond VM; Talasaz A; Boland GM; Corcoran RB
Clin Cancer Res; 2021 Oct; 27(20):5586-5594. PubMed ID: 33926918
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study.
Ohara S; Suda K; Sakai K; Nishino M; Chiba M; Shimoji M; Takemoto T; Fujino T; Koga T; Hamada A; Soh J; Nishio K; Mitsudomi T
Transl Lung Cancer Res; 2020 Oct; 9(5):1915-1923. PubMed ID: 33209612
[TBL] [Abstract][Full Text] [Related]
20. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer.
Grunnet M; Sorensen JB
Lung Cancer; 2012 May; 76(2):138-43. PubMed ID: 22153832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]